WO2012043393A1 - Émulsion - Google Patents

Émulsion Download PDF

Info

Publication number
WO2012043393A1
WO2012043393A1 PCT/JP2011/071658 JP2011071658W WO2012043393A1 WO 2012043393 A1 WO2012043393 A1 WO 2012043393A1 JP 2011071658 W JP2011071658 W JP 2011071658W WO 2012043393 A1 WO2012043393 A1 WO 2012043393A1
Authority
WO
WIPO (PCT)
Prior art keywords
weight
oil
emulsion composition
terpene
acid
Prior art date
Application number
PCT/JP2011/071658
Other languages
English (en)
Japanese (ja)
Inventor
和克 阿度
Original Assignee
小林製薬株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 小林製薬株式会社 filed Critical 小林製薬株式会社
Publication of WO2012043393A1 publication Critical patent/WO2012043393A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/31—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to an emulsified composition, an external preparation for skin, and an analgesic.
  • an oil-in-water emulsion composition in which oil components are dispersed in water is a mixture of water and oil components stably by the action of the emulsifier, and is widely used in pharmaceuticals, cosmetics, etc. as high-value-added preparations. ing. *
  • Patent Document 1 discloses a skin external preparation composition containing an ester steroid and menthol, which are effective as a therapeutic agent for atopic dermatitis. However, only creams are shown here that do not require stability.
  • Another object of the present invention is to provide an emulsified composition, an external preparation for skin, and an analgesic that solve the above-mentioned problems and are excellent in heat stability in a semi-solid state and have a good feeling when applied to the skin. .
  • the present invention is an emulsified composition containing water, an oily component, a hydrophilic surfactant and a terpene, wherein the oily component is added in an amount of 0.2 to 0.7 parts by weight with respect to 1 part by weight of the water.
  • the present invention relates to an emulsion composition comprising 0.37 to 1.0 part by weight of the hydrophilic surfactant and 0.08 to 0.45 part by weight of the terpene with respect to 1 part by weight of an oil component.
  • the oil component is preferably liquid at normal temperature.
  • the oily component preferably contains liquid paraffin in an amount of 25% by weight or more in 100% by weight of the oily component.
  • the hydrophilic surfactant preferably contains 30% by weight or more of polyoxyethylene cetyl ether of HLB 8 to 13.5 in 100% by weight of the hydrophilic surfactant.
  • the terpene is preferably a monoterpene.
  • the monoterpene is preferably a cyclic monoterpene.
  • the said emulsion composition is an oil-in-water type emulsion composition.
  • This invention is also a skin external preparation which consists of the said emulsion composition.
  • the present invention is also an analgesic comprising the above emulsion composition.
  • the present invention is an emulsified composition containing specific amounts of water, an oil component, a hydrophilic surfactant and a terpene, it is excellent in thermal stability in a liquid to semi-solid state and is applied to the skin. The feeling when used is also good.
  • the emulsified composition of the present invention contains water, an oily component, a hydrophilic surfactant and a terpene in specific amounts.
  • a compound that can be used as a refreshing agent or a fragrance component When a compound that can be used as a refreshing agent or a fragrance component is applied to an emulsion stabilizer for essentially different uses, it usually tends to reduce stability.
  • a specific compound called terpene is used, and since the terpene is mixed with water, an oil component, and a hydrophilic surfactant in specific amounts, the heat stability is extremely high.
  • An emulsified composition (emulsified preparation) excellent in the above can be prepared. *
  • terpenes which have been known to be destabilized, are limited to emulsion compositions of a specific formulation as in the present invention as stabilizers.
  • the knowledge of functioning is contrary to conventional technical common sense and has an effect that cannot be predicted at all. Furthermore, finding specific formulations using such terpenes is associated with great difficulty.
  • water examples include purified water, distilled water, sterilized water, physiological saline, deep sea water, and the like, preferably purified water.
  • the oil component (oil phase) is a component constituting the oil droplets (oil phase) of the emulsion composition (oil-in-water emulsion composition).
  • the emulsion composition oil-in-water emulsion composition
  • olive oil, wheat germ oil, rice bran oil, safflower oil, soybean oil, camellia oil, corn oil, rapeseed oil, sunflower oil, cottonseed oil, peanut oil are commonly used in pharmaceuticals, quasi drugs, cosmetics, etc.
  • Vegetable oil such as lard, fish oil, animal oil such as squalane and beeswax, liquid paraffin, gelled hydrocarbon, mineral oil such as petrolatum, lecithin derivatives such as soybean lecithin, isopropyl myristate, isopropyl palmitate, cetyl palmitate, sebacic acid Fatty acid esters such as diethyl and ethyl oleate, silicones such as dimethyl silicone and cyclic silicone, fatty acids such as oleic acid and linoleic acid, hormones such as ethinyl estradiol, fennel oil, clove oil, peppermint oil, eucalyptus oil, Essential oils such as lemon oil And the like. Silicon oil, waxes and the like are also included. *
  • higher alcohol is mentioned as another oil-based component.
  • the higher alcohol include aliphatic alcohols having 6 or more carbon atoms. Specific examples include cetanol, behenyl alcohol, myristyl alcohol, cetyl alcohol, oleyl alcohol, stearyl alcohol, hexadecyl alcohol, lanolin alcohol and the like. *
  • the oil component is preferably liquid at room temperature (25 ° C.) from the viewpoint of ensuring the fluidity of the emulsion composition.
  • vegetable oils, animal oils, mineral oils, and fatty acid esters are preferable, and animal oils, mineral oils, and fatty acid esters are more preferable because an emulsion composition having excellent heat stability and fluidity can be prepared.
  • liquid paraffin is preferably used alone or in combination as a mineral oil.
  • An oil component may be used independently and may use 2 or more types together. *
  • the blending amount of the oil component is 0.2 to 0.7 parts by weight, preferably 0.22 to 0.50, based on 1 part by weight of water from the viewpoint of thermal stability. Part by weight, more preferably 0.22 to 0.45 part by weight.
  • the emulsion composition of this invention it is preferable to contain 25 weight% or more of liquid paraffin in 100 weight% of oily components. Thereby, the outstanding thermal stability and fluidity
  • liquidity are obtained. More preferably, it is 27 weight% or more, More preferably, it is 29 weight% or more.
  • the upper limit is not particularly limited, but is preferably 90% by weight or less, more preferably 80% by weight or less.
  • the hydrophilic surfactant preferably has an HLB of 8 to 18.0, more preferably 8 to 13.5.
  • HLB is an abbreviation for hydrophile-lipophile balance, and is known as one of the indexes representing the effect of surfactants. The higher the HLB value, the higher the hydrophilicity.
  • a weighted average value is said. *
  • the hydrophilic surfactant is not particularly limited as long as it is usually used in pharmaceuticals, quasi drugs, cosmetics, etc. From the viewpoint of thermal stability and fluidity, a nonionic hydrophilic surfactant is used. preferable.
  • a polyoxyethylene (hereinafter referred to as POE) addition type surfactant is suitable, for example, POE (10 to 50 mol) phytosterol ether, POE (10 to 50 mol) dihydro Cholesterol ether, POE (10-50 mol) 2-octyldodecyl ether, POE (10-50 mol) decyl tetradecyl ether, POE (10-50 mol) oleyl ether, POE (10-50 mol) cetyl ether, POE ( Polyoxyethylene alkyl ethers such as 5-30 mol) polyoxypropylene (5-30 mol) 2-decyltetradecyl ether, POE (10-50 mol) polyoxypropylene (2-30
  • polyoxyethylene cetyl ether a mixture of this and polyethylene glycol mono (di) stearate, polyoxyethylene cetyl ether sodium phosphate, one or more polyoxyethylene polyoxypropylene cetyl ethers
  • polyoxyethylene cetyl ether a mixture of this and polyethylene glycol mono (di) stearate, polyoxyethylene cetyl ether sodium phosphate, one or more polyoxyethylene polyoxypropylene cetyl ethers
  • polyoxyethylene cetyl ether having an HLB of 8 to 13.5 is particularly preferred.
  • a hydrophilic surfactant may be used independently and may use 2 or more types together. *
  • the blending amount of the hydrophilic surfactant is 0.37 to 1.0 part by weight, preferably 0.39 with respect to 1 part by weight of the oil component, from the viewpoint of thermal stability. Is 0.91 part by weight, more preferably 0.42 to 0.75 part by weight.
  • the emulsified composition of the present invention it is preferable to contain 30% by weight or more of polyoxyethylene cetyl ether of HLB 8 to 13.5 in 100% by weight of the hydrophilic surfactant. Thereby, the outstanding thermal stability and fluidity
  • liquidity are obtained. More preferably, it is 33% by weight or more.
  • the upper limit is not particularly limited, but is preferably 90% by weight or less, more preferably 80% by weight or less. *
  • Terpenes include monoterpenes, hemiterpenes, sesquiterpenes, etc., specifically, terpene hydrocarbons, terpene series Examples include alcohols, terpene aldehydes, and terpene ketones.
  • terpene hydrocarbon examples include monoterpene hydrocarbons such as limonene, pinene and camphor, and sesquiterpene hydrocarbons such as lysine.
  • terpene alcohol examples include monoterpene alcohols such as citronellol, geraniol, linalool, menthol, terpineol, and borneol, sesquiterpene alcohols such as farnesol, diterpene alcohols, and the like.
  • terpene aldehyde examples include monoterpene aldehydes such as citronellal, citral and safranal, and diterpene aldehydes such as retinal.
  • terpene ketones examples include monoterpene ketones such as menthone, carbomenton, and yonon. These terpenes may be any of d-, l- and dl-forms.
  • terpenes are preferable, and cyclic monoterpenes are more preferable.
  • a terpene may be used independently and may use 2 or more types together.
  • the blending amount of the terpene is 0.08 to 0.45 parts by weight, preferably 0.08 to 0.43 parts per 1 part by weight of the oil component from the viewpoint of thermal stability. Parts by weight, more preferably 0.08 to 0.39 parts by weight.
  • the viscosity of the emulsified composition of the present invention is preferably 4000 to 150,000 cP, more preferably 10,000 to 130,000 cP, from the viewpoints of thermal stability and usability upon application to the skin.
  • the viscosity is a value measured by the following method using a viscometer “model: LVDV-II + (BROOK FIELD, manufactured by Spindle E type)”. (Method) 35 g of a sample (emulsified composition) is placed in a sample container of a Maruemu screw tube (No. 7) and measured at 4.0 RPM while moving up and down at room temperature (around 25 ° C.). The intermediate value is used as the measured value. *
  • the emulsion composition of this invention can manufacture as follows. Water, oil component, hydrophilic surfactant, terpene, and other ingredients such as medicinal ingredients, higher alcohols, and fragrances are mixed as necessary, heated to 65.0-85.0 ° C, and then mixed with a homogenizer
  • the emulsified product of the present invention can be prepared by emulsification by a known method such as emulsification under a predetermined condition using a machine.
  • Stabilizer Dibutylhydroxytoluene, sodium edetate, sodium sulfite, dry sodium sulfite and the like. *
  • Thickener xanthan gum, hypromellose (hydroxypropylmethylcellulose), hydroxypropylcellulose, macrogol 400, macrogol 1500, macrogol 4000, carboxyvinyl polymer and the like. *
  • Preservatives butyl paraben, methyl paraben, propyl paraben, ethyl paraben, sodium benzoate, benzyl alcohol and the like. *
  • Buffer borate buffer, phosphate buffer, carbonate buffer, citrate buffer, acetate buffer, epsilon-aminocaproic acid, aspartic acid, aspartate, etc. *
  • pH adjusters inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, polyphosphoric acid, boric acid; lactic acid, acetic acid, citric acid, tartaric acid, malic acid, succinic acid, oxalic acid, gluconic acid, fumaric acid, propionic acid, acetic acid, Organic acids such as aspartic acid, epsilon-aminocaproic acid, glutamic acid, aminoethylsulfonic acid; inorganic bases such as sodium hydrogen carbonate, sodium carbonate, potassium hydroxide, sodium hydroxide, calcium hydroxide, magnesium hydroxide; monoethanolamine, Organic salts such as triethanolamine, diisopropanolamine, triisopropanolamine and lysine. *
  • the form of the emulsified composition of the present invention is a liquid to semi-solid oil-in-water emulsified composition, which contains medicinal ingredients and the like according to the affected area, application method, etc. to be applied, and is appropriately set. It can be suitably used as an external preparation for skin, and a therapeutic effect can be obtained.
  • the emulsified composition has fluidity in a liquid to semi-solid state, so that it is easy to take in use, has good spreadability, has little stickiness, is easy to adjust to the skin, and has little irritation. Therefore, it can be suitably applied to a layer such as women who place importance on sensory elements such as tactile sensation and vision. *
  • the external preparation for skin include liquid to semisolid creams, emulsions, lotions and the like.
  • preferable forms include emulsions and lotions.
  • it can be suitably used as an analgesic.
  • an anti-inflammatory analgesic it is possible to loosen or heal muscles by applying to the affected area of stiff shoulders or muscle fatigue.
  • the above-mentioned external preparation for skin can be blended with active ingredients as long as the effects of the present invention are not impaired.
  • active ingredients include steroids (dexamethasone, dexamethasone hydrochloride, dexamethasone acetate, hydrocortisone hydrochloride, prednisolone valerate, prednisolone acetate, etc.), antihistamines (diphenhydramine, diphenhydramine hydrochloride, chlorpheniramine maleate, etc.), local anesthetics (lidocaine) , Dibucaine, procaine, tetracaine, bupipacaine, mepipacaine, chloroprocaine, proparacaine, meprilucaine or a salt thereof, alkyl benzoate (for example, ethyl aminobenzoate, diethylaminoethyl parabutylaminobenzoate hydrochloride), orthocaine, oxesasein, oxypolyen
  • such physical pain is not particularly limited, but is caused by external stimuli such as trauma, aging, or poor It may be caused by things such as posture, long working hours, maintaining a stationary posture for a long time, excessive exercise, or mental stress.
  • external stimuli such as trauma, aging, or poor It may be caused by things such as posture, long working hours, maintaining a stationary posture for a long time, excessive exercise, or mental stress.
  • the pain that can be treated include neuralgia, joint pain, low back pain, muscle pain, stiff shoulder pain, fracture pain, bruise pain, sprain pain, trauma pain, headache, post-operative pain and the like.
  • neuralgia low back pain, muscle pain, stiff shoulder pain, and joint pain caused by aging, poor posture, long working hours, etc.
  • low back pain muscle pain, stiff shoulder pain, and joint pain.
  • analgesia it can be used for the purpose of anti-inflammation (anti-inflammatory) and / or fatigue and fatigue.
  • Examples 1 to 14 and Comparative Examples 1 to 8 According to the prescriptions shown in Tables 1 to 3, the ingredients were mixed and heated to 65 ° C. or higher, and then homogenizer “ROBOMICS (manufactured by TOKUSYU KIKA)” Emulsification was performed at 12,500 rpm for 3 minutes. Then, it cooled to room temperature, stirring, and obtained the emulsion composition.
  • ROBOMICS manufactured by TOKUSYU KIKA
  • HLB of each hydrophilic surfactant and a brand name are as follows.
  • Polyoxyethylene cetyl ether (BC-5.5): HLB 10.5 (manufactured by Nikko Chemicals)
  • Polyoxyethylene cetyl ether (BC-23): HLB 18 (manufactured by Nikko Chemicals)
  • Polyethylene glycol monostearate-100: HLB 18 (Nikko Chemicals) (Made by company)
  • the thermal stability of the obtained emulsion composition was evaluated by the following method. Moreover, the viscosity of the emulsion composition was measured by the above-mentioned method. The results are shown in Tables 1-3. *
  • Example 5 From the results of Example 5 and Comparative Example 1, it was revealed that l-menthol exhibited an action of stabilizing the emulsion composition. In addition, in Examples 1 to 3 and 11 and Comparative Examples 2 to 3, it was proved that the stabilizing effect was exhibited by adjusting l-menthol to a specific amount. Further, from Comparative Examples 4 to 6, it has become clear that it is important to adjust the hydrophilic surfactant to a specific amount and from Comparative Examples 7 to 8 to adjust the oil component to a specific amount. *

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Cette invention concerne une émulsion, une préparation pour la peau à usage externe et un antalgique, chacun d'eux se trouvant à l'état semi‑solide, ayant une excellente stabilité thermique et produisant une bonne sensation lors de l'application cutanée. L'émulsion de l'invention contient de l'eau, un composant huileux, un tensioactif hydrophile et un terpène, et est caractérisée en ce que le composant huileux est présent en une quantité de 0,2 à 0,7 partie en poids pour 1 partie en poids d'eau, et le tensioactif hydrophile et le terpène sont présents en des quantités de 0,37 à 1,0 partie en poids et de 0,08 à 0,45 partie en poids respectivement pour 1 partie en poids du composant huileux.
PCT/JP2011/071658 2010-09-30 2011-09-22 Émulsion WO2012043393A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010-223056 2010-09-30
JP2010223056A JP5912238B2 (ja) 2010-09-30 2010-09-30 乳化組成物

Publications (1)

Publication Number Publication Date
WO2012043393A1 true WO2012043393A1 (fr) 2012-04-05

Family

ID=45892844

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2011/071658 WO2012043393A1 (fr) 2010-09-30 2011-09-22 Émulsion

Country Status (2)

Country Link
JP (1) JP5912238B2 (fr)
WO (1) WO2012043393A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6537775B2 (ja) * 2014-03-10 2019-07-03 小林製薬株式会社 乳化組成物
JP6336299B2 (ja) * 2014-03-10 2018-06-06 小林製薬株式会社 サリチル酸エステル含有乳化組成物
JP6289202B2 (ja) * 2014-03-26 2018-03-07 小林製薬株式会社 乳化型医薬組成物

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US281996A (en) * 1883-07-24 Thieds to james f
JPS63119420A (ja) * 1986-11-08 1988-05-24 Hisamitsu Pharmaceut Co Inc 泡状エアゾ−ル消炎鎮痛製剤
WO1992016237A1 (fr) * 1991-03-20 1992-10-01 Hisamitsu Pharmaceutical Co., Inc. Composition soulageant les irritations cutanees et preparation pour administration percutanee a usage externe contenant ladite composition
JPH09157172A (ja) * 1995-12-13 1997-06-17 Lion Corp 皮膚外用剤及び湿疹薬
JP2000273061A (ja) * 1999-03-19 2000-10-03 Senju Pharmaceut Co Ltd テルペノイドエマルション
JP2007320873A (ja) * 2006-05-31 2007-12-13 Mandom Corp 防腐殺菌剤組成物
JP2009114083A (ja) * 2007-11-02 2009-05-28 Maruzen Pharmaceut Co Ltd 抗菌剤及び皮膚外用剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998000168A1 (fr) * 1996-07-02 1998-01-08 Novartis Consumer Health S.A. Composition topique contenant une combinaison de composes antihistaminiques et de composes terpenoides

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US281996A (en) * 1883-07-24 Thieds to james f
JPS63119420A (ja) * 1986-11-08 1988-05-24 Hisamitsu Pharmaceut Co Inc 泡状エアゾ−ル消炎鎮痛製剤
WO1992016237A1 (fr) * 1991-03-20 1992-10-01 Hisamitsu Pharmaceutical Co., Inc. Composition soulageant les irritations cutanees et preparation pour administration percutanee a usage externe contenant ladite composition
JPH09157172A (ja) * 1995-12-13 1997-06-17 Lion Corp 皮膚外用剤及び湿疹薬
JP2000273061A (ja) * 1999-03-19 2000-10-03 Senju Pharmaceut Co Ltd テルペノイドエマルション
JP2007320873A (ja) * 2006-05-31 2007-12-13 Mandom Corp 防腐殺菌剤組成物
JP2009114083A (ja) * 2007-11-02 2009-05-28 Maruzen Pharmaceut Co Ltd 抗菌剤及び皮膚外用剤

Also Published As

Publication number Publication date
JP5912238B2 (ja) 2016-04-27
JP2012077027A (ja) 2012-04-19

Similar Documents

Publication Publication Date Title
JP2023086619A (ja) 乳化組成物
JP6903410B2 (ja) 水中油型乳化組成物
JP5769481B2 (ja) ウフェナマート含有皮膚外用剤
JP7170384B2 (ja) 乳化組成物
TWI806867B (zh) 乳化組成物
JP5912238B2 (ja) 乳化組成物
JP6753312B2 (ja) 医療用皮膚外用剤
JP7170385B2 (ja) 乳化組成物
JP6726498B2 (ja) 外用組成物
JP7449692B2 (ja) 油性外用組成物
JP2004210669A (ja) ユビキノン含有組成物、及び該ユビキノン含有組成物を用いた乳化組成物
JP7312527B2 (ja) 乳化組成物
JP2018002685A (ja) 乳化組成物
JP6336299B2 (ja) サリチル酸エステル含有乳化組成物
JP7499024B2 (ja) 外用組成物
JP7500193B2 (ja) 乳化組成物
JP7499023B2 (ja) 外用組成物
JP6537775B2 (ja) 乳化組成物
JP7398274B2 (ja) 外用組成物
JP4731472B2 (ja) 徐放性クリーム剤
JP7465066B2 (ja) 乳化安定化剤
JP6289202B2 (ja) 乳化型医薬組成物
JP2023090338A (ja) 乳化組成物
WO2008038806A1 (fr) Agent antipruritique
JP2022097835A (ja) 水中油型乳化組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11828949

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11828949

Country of ref document: EP

Kind code of ref document: A1